Medical Professionals Reference (MPR)ADA: Once-Daily Orforglipron Linked to Significant Weight Reduction

By week 36, 46 to 75% of patients on orforglipron had lost at least 10% of their body weight.

Orforglipron, a once-daily oral GLP-1 receptor agonist, caused adults with obesity or overweight to lose weight in a way that was clinically significant, according to a study that was released online in the New England Journal of Medicine on June 23 to coincide with the American Diabetes Association’s annual meeting, which was held from June 23 to 26 in San Diego.

Key Points:

• A total of 272 patients were randomly randomized to receive orforglipron once daily for 36 weeks at doses of 12, 24, 36, or 45 mg, or a placebo.
• The mean change from baseline in body weight ranged from −9.4% to −14.7% with orforglipron and was −2.3% with placebo at 36 weeks.
• A weight reduction of at least 10% occurred in 46% to 75% receiving orforglipron and 9% receiving placebo; a weight reduction of at least 15% occurred in 48% and 1% of those receiving orforglipron 45mg and placebo, respectively.

Additonal Points:

• The safety profile was consistent with that of the GLP-1 receptor agonist class.

Conclusion:

• Further studies are needed to establish whether the health benefits seen with injectable GLP-1 receptor agonists are shared by orforglipron.

Endocrinology Latest Posts

• Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 DiabetesApril 19, 2024
• Are Plant-based Meat Substitutes Really Better for the Heart than Meat Options?April 17, 2024
• Corticosteroids: Giving and Taking AwayApril 15, 2024
• Acquired Reactive Perforating Collagenosis in a Patient with DiabetesApril 15, 2024

Did You Know?
According to the CDC, more than 42% of adults in the United States are obese.